Upstream Bio reports Q2 2026 results, COPD enrollment complete, Phase 3 on track for Q1 2027
The company said end-of-Phase 2 talks with the FDA remain on schedule as it prepares Phase 3 trials in severe asthma and CRSwNP for verekitug.
Upstream Bio reported second quarter 2026 financial results and business updates on August 11, 2026, for the period ended June 30, 2026. The company reported financial results and business updates for the quarter ended June 30, 2026, highlighting continued progress in developing verekitug across three target indications: severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).1
The company said it remains on track to initiate Phase 3 clinical trials in severe asthma and CRSwNP in the first quarter of 2027, with end-of-Phase 2 interactions with the FDA for both indications also on track.1 The company has previously said it plans to pursue a Phase 3 strategy using a high-dose quarterly regimen in broad patient populations for both indications.1
In COPD, Upstream Bio completed enrollment in its Phase 2 VENTURE trial with 481 participants, with data expected in the second half of 2027.1 VENTURE (NCT06981078) is a Phase 2, global, randomized, double-blind, placebo-controlled, parallel-group trial assessing verekitug in moderate-to-severe COPD patients across 12- and 24-week extended dosing intervals.1
The company also updated its long-term extension study in severe asthma. Eligible participants who completed the Phase 2 VALIANT trial were offered enrollment in VALOUR (NCT06966479), a long-term extension study, which completed enrollment in March 2026 with more than 90% retention of eligible VALIANT participants, with data expected in the second half of 2027.1
On the CRSwNP data front, post-hoc responder analyses presented at the EAACI Congress in June 2026 showed that verekitug, dosed once every three months, led to clinically meaningful improvements in nasal polyp score in about 80% of participants, with 72% improving in nasal congestion and 83% in CRSwNP total symptom score.1
On financials, as of June 30, 2026, Upstream Bio had cash, cash equivalents and short-term investments of $261.3 million, which the company said is expected to fund planned operations through 2027.1 Net loss was $39.7 million for the quarter, compared to a net loss of $40.0 million for the same period in 2025.1
Looking ahead, Upstream Bio said it expects to participate in the European Respiratory Society Congress 2026, September 5-9, in Barcelona.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.